Hearing Loss Trial, Recruiting (NCT07635368)

Hearing Loss Trial, Recruiting NCT07635368 Sponsor: Rigshospitalet, Denmark Condition: Hearing Loss

Printed from Voxsanity (voxsanity.com.au) — NCT07635368 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Hearing Loss

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Children born between January 1, 2010 and December 31, 2025 who have a newborn blood spot sample stored from the Danish national newborn screening program
Children who tested positive for a birth infection called congenital CMV (cytomegalovirus), confirmed by a test done shortly after birth (these children are the "cases" in the study)
Children without signs of this birth infection, who are similar in sex, gestational age, birth weight, and age when their newborn blood spot was taken (these children are the "controls" or comparison group in the study)

Who may not be able to join:

Children whose stored newborn blood spot sample has not been approved for use in research
Children whose stored newborn blood spot sample does not contain enough blood material to carry out the required laboratory tests
Children whose stored blood spot sample is not of good enough quality to produce reliable test results

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Kia Hee Schultz Dungu, MD, Rigshospitalet, Denmark

Phone: +45 22645782

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07635368

Sponsor: Rigshospitalet, Denmark

Phase: Not Applicable

Status: Recruiting

Condition: Hearing Loss

Trial contact: +45 22645782

More information: https://clinicaltrials.gov/study/NCT07635368

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Children born between January 1, 2010 and December 31, 2025 who have a newborn blood spot sample stored from the Danish national newborn screening program
Children who tested positive for a birth infection called congenital CMV (cytomegalovirus), confirmed by a test done shortly after birth (these children are the "cases" in the study)
Children without signs of this birth infection, who are similar in sex, gestational age, birth weight, and age when their newborn blood spot was taken (these children are the "controls" or comparison group in the study)

Who may not be able to join:

Children whose stored newborn blood spot sample has not been approved for use in research
Children whose stored newborn blood spot sample does not contain enough blood material to carry out the required laboratory tests
Children whose stored blood spot sample is not of good enough quality to produce reliable test results

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Rigshospitalet, Denmark

Registry

ClinicalTrials.gov

Start date

21 April 2026

Est. completion

30 September 2026

Where this trial is recruiting

🇩🇰 Denmark

Primary endpoints

Differential protein expression associated with sequelae following congenital cytomegalovirus infection; Differential host RNA expression associated with sequelae following congenital cytomegalovirus infection

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov